4Dcell’s Post

🎉I'm thrilled to announce the release of the publication in eLife regarding the 3D cardiac organoid that we developped with PARCC. The 4Dcell SmartHeart represents a significant breakthrough in physiologically relevant ring-shaped contractile assays for academic, efficacy, and toxicity studies. SmartHeart + AI opens up new frontiers in cardiac health. ▶️Discover the SmartHeart beating by watching the video here: https://lnkd.in/eTkRk4Jm

Organoids Derived from HNSCC Patients Aid in Testing Drug Sensitivity and Resistance. #Organoid #HPVNegativeHeadAndNeckSquamousCellCarcinomaOrganoids Learn more: https://lnkd.in/eaziYcQK

Advancements in Treating Richter Transformation: CAR T-Cell Therapy or Allo-SCT?: Experts debate over the most effective treatment pathway for Richter transformation, highlighting the risks and benefits of different cellular therapies. #finance #pharmacy #lifesciences

https://lnkd.in/gyn9WeSn How cool is this? CardiaTec is utilising AI to help them discover new treatments for cardiovascular diseases. Using the power of AI for good will revolutionise the pharmaceutical industry, potentially providing a faster and more efficient way to provide life-saving treatments. #AI

#Microplastics and #Nanoplastics in Atheromas and #Cardiovascular Events Microplastics and nanoplastics (MNPs) are emerging as a potential risk factor for cardiovascular disease in preclinical studies. In this study, patients with carotid artery plaque in which MNPs were detected had a higher risk of a composite of myocardial infarction, stroke, or death from any cause at 34 months of follow-up than those in whom MNPs were not detected (hazard ratio, 4.53; 95% confidence interval, 2.00 to 10.27; P<0.001). #toxicology #publichealth https://lnkd.in/dmu655jd

Looking to build in vitro cardiotoxicity and cardiac disease models? Read about our work and download our new 2024 Cardiac Guide! Last week, we attended the Society of Toxicology 63rd Annual Meeting and ToxExpo, discussing our work using human iPSCs for cardiotoxicity and neurotoxicity screening. We received an incredible response to our cardiotoxicity offerings, including: • A new axoCells™ Atrial Kit product, offering an all-in-one bundle for in vitro atrial fibrillation modeling • Two exciting concepts that we're working on, with a view to enhancing the purity and maturity of iPSC-derived cardiotoxicity models • Our range of capabilities to support cardiac safety researchers including custom lab services, iPSCs and collaborative model building We've rounded up our cardiac and cardiotoxicity offerings into our 2024 Cardiac Guide, which you can download by clicking the link in the article below. https://hubs.la/Q02pMYMs0 If you'd like to discuss a project, get in contact at operations@axolbio.com #iPSCs #cardiotoxicity #CiPA #AtrialFibrillation #SOT2024

Interesting read on optimizing sirolimus dosing for hematopoietic cell transplant (HCT) patients undergoing post-transplantation cyclophosphamide (PTCy) to prevent graft-versus-host disease (GVHD). Current data inconsistencies emphasize the need for phase I studies and systematic research to refine quantitative systems pharmacology models. #biotech #qsp #translationalmedicine

From the rapid development of at-home test kits to advances in point-of-care testing, the in vitro diagnostics (IVD) industry has drastically evolved in recent years. Click to learn how point-of-care and molecular assays are shaping medicine.

A recent study by Han et. al found milk-derived exosomes (M-Exos) have remarkable structural stability, making them efficient siRNA carriers, with the potential to overcome the difficulties associated with oral RNA drug delivery through the gastrointestinal tract. Research such as this shows that there is growing demand for – and interest in – effective delivery systems for oral RNA treatments. Nuvec®’s characteristic ‘spiky’ particles offer protection to siRNA from enzymatic attack. Further processing to provide a powdered form allows incorporation of the siRNA/Nuvec® intermediate to be incorporated into enteric-protected capsules (and potentially compressed into tablets) for targeting to particular gastrointestinal locations. Read ‘Oral TNF-α siRNA delivery via milk-derived exosomes for effective treatment of inflammatory bowel disease’ by Han et al. to find out more: https://lnkd.in/eNf8Dz7z To subscribe to regular updates from our investor hub, visit https://lnkd.in/e-G_-SmJ #siRNA #oraldrugdelivery #IBD  

📰 INDIGO In Action 📰 This recent publication titled "Preclinical evaluation of ELP‐004 in mice" utilizes INDIGO's PXR, LCMA, AhR, and CAR3 assay kits! "This study provides a detailed understanding of the preclinical pharmacokinetics and metabolism of ELP‐004, an osteoclast inhibitor in development for the treatment of bone erosion. Current treatments for arthritis, including biological disease‐modifying antirheumatic drugs, are not well‐tolerated in a substantial subset of arthritis patients and are expensive; therefore, new treatments are needed. Pharmacokinetic parameters of ELP‐004 were tested with intravenous, oral, and subcutaneous administration and found to be rapidly absorbed and distributed." Read now by clicking on the link below 🎉 https://bit.ly/3WLjBrb